Cleantech Blue-Zone Technologies Signs Agreement With Respirair Global
Blue-Zone to install its patented anesthetic capture technology in Respirair manufacturing facility TORONTO, April 11,…
Month: April 2023
Cleantech Blue-Zone Technologies Signs Agreement With Respirair Global
Blue-Zone to install its patented anesthetic capture technology in Respirair manufacturing facility TORONTO, April 11,…
Humacyte Completes Enrollment in Phase 3 Trial of Human Acellular Vessel™ (HAV™) for Hemodialysis Access in End-Stage Renal Disease Patients
DURHAM, N.C., April 11, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology…
Humacyte Completes Enrollment in Phase 3 Trial of Human Acellular Vessel™ (HAV™) for Hemodialysis Access in End-Stage Renal Disease Patients
DURHAM, N.C., April 11, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology…
Collegium to Participate in 22nd Annual Needham Virtual Healthcare Conference
STOUGHTON, Mass., April 11, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified…
Collegium to Participate in 22nd Annual Needham Virtual Healthcare Conference
STOUGHTON, Mass., April 11, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified…
Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting
SALT LAKE CITY, April 11, 2023 (GLOBE NEWSWIRE) — Clene Inc. (NASDAQ: CLNN) (along with…
Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting
SALT LAKE CITY, April 11, 2023 (GLOBE NEWSWIRE) — Clene Inc. (NASDAQ: CLNN) (along with…
Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
SAN JOSE, Calif., April 11, 2023 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”…
Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
SAN JOSE, Calif., April 11, 2023 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”…
INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03
Two presentations show targeting high-risk MUC4 expressing HER2+ and Triple Negative Breast Cancer with INB03…
INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03
Two presentations show targeting high-risk MUC4 expressing HER2+ and Triple Negative Breast Cancer with INB03…
Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology
NEW YORK and LONDON, April 11, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology
NEW YORK and LONDON, April 11, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting
Updated data on durability of responses and long-term complete responses (CRs) in leukemia patients treated…
IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting
Updated data on durability of responses and long-term complete responses (CRs) in leukemia patients treated…
Chinook Therapeutics Announces Voluntary Pause in Dosing of CHK-336 in Ongoing Phase 1 Clinical Trial in Healthy Volunteers
SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company…
Chinook Therapeutics Announces Voluntary Pause in Dosing of CHK-336 in Ongoing Phase 1 Clinical Trial in Healthy Volunteers
SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company…
eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer
The Company’s eIF4A inhibitor, zotatifin, will be tested in specific genomically-defined subgroups, including standard risk…
eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer
The Company’s eIF4A inhibitor, zotatifin, will be tested in specific genomically-defined subgroups, including standard risk…